



Heart in Diabetes (HiD) 2025

June 6-8, 2025; Philadelphia, PA; Resource Hub – Draft

Welcome to our resource hub for [Heart in Diabetes 2025!](#) This is a one-stop-shop for all your Heart in Diabetes (HiD) needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

Important Conference Information. The Heart in Diabetes Conference is on its eighth year of educating attendees on best practices incorporating emerging clinical trial data into clinical practice. The program will focus on early interventions and other topics including obesity’s impact on the heart and kidneys, women’s health, diabetes management, the role of digital health and technology, and more unique topics in the cardio-renal-metabolic ecosystem!

Table of Contents

[Useful Conference Links](#)

[Day-of Conference Reports](#)

[Diabetes Therapy Highlights](#)

[Diabetes Technology Highlights](#)

[Diabetes Big Picture Highlights](#)

[Previous Heart in Diabetes Coverage on CCKB](#)

Useful Conference Links

1. [Conference Website](#)
2. [Conference Registration](#)
3. [Day-by-Day Conference Preview](#)
4. [Conference Program](#)

Day-of Conference Reports

1. [Day #1 Highlights](#)
2. [Day #2 Highlights](#)
3. [Day #3 Highlights](#)

Diabetes Therapy Highlights

1. [The need for an accelerated, risk-based approach](#) in CKD management was stressed throughout early presentations
2. [From brain to lungs, prediabetes to old age:](#) Drs. Plutzky, Selvin, Grant, and Pratley review diabetes comorbidities
3. [Dr. Kahn pushes for more optimal screening strategies](#) for heart failure, highlighting WATCH-DM score and NT-proBNP biomarker
4. [MAGMA trial reveals](#) how mineralocorticoid receptor antagonists (Bayer’s Kerendia) reduce CV risks in T2D and CKD
5. [Cortisol and cardiorenalmetabolic diseases:](#) Insights from the CATALYST trial across endocrinology, kidney, CV, and bone health
6. [Managing dyslipidemia](#) in women throughout different stages
7. [Luminary in Cardiometabolic Medicine Award:](#) Dr. Darren McGuire on the evolution of cardiovascular outcomes

assessment of antihyperglycemic medications

8. [Dr. Ralph DeFronzo explores](#) the potential mechanisms of GLP-1 RAs for the prevention of cardiovascular disease
9. [Dr. Silvio Inzucchi](#) on the expanding roles of SGLT-2 inhibitors in CKM, T1D, and beyond
10. [Dr. Jennifer Green discusses uses of GLP-1 RAs](#) under investigation and therapeutic challenges: durability, body composition, and clinical comparators
11. [Prof. Mark Kearney](#) on the mechanisms and future directions of diabetic cardiomyopathy
12. [Dr. Ann Marie Navar advocates](#) for the use of Apolipoprotein B to assess ASCVD risk rather than LDL cholesterol

Diabetes Technology Highlights

1. [Diabetes technology in dialysis](#), cardiovascular disease, and inpatient management

Diabetes Big Picture Highlights

1. [Former FDA Commissioner Dr. Robert Califf](#): Health technology can address challenges facing US cardiometabolic care, but broad healthcare reform is essential
2. [Epidemiological trends of heart failure in the US](#): complications and rural access challenges on the rise
3. [High proportion of obesity-related conditions](#) is directly attributable to obesity and overweight in US adolescents and young adults

Previous Heart in Diabetes Coverage on CCKB

1. [HiD 2024 Resource Hub](#)
2. [HiD 2023 Resource Hub](#)
3. [HiD 2022 Resource Hub](#)
4. [HiD 2021 Resource Hub](#)
5. [HiD 2020 Resource Hub](#)
6. [HiD 2019 Full Report](#)